User:Mr. Ibrahem/Vibegron

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Vibegron
Clinical data
Trade namesGemtesa
Other namesRVT-901; MK4618; KRP114V; URO-901
AHFS/Drugs.comMonograph
License data
Routes of
administration		By mouth
Drug classBeta3 adrenergic receptor agonist
Legal status
Legal status
Pharmacokinetic data
Protein binding49.6 to 51.3% is bound to plasma proteins [2]
MetabolismPredominantly oxidation and glucuronidation [2]
Elimination half-life60 to 70 hours [2]
Excretion59% feces (54% of this is in the unchanged parent drug form), 20% urine (19% of this is in the unchanged parent drug form) [3]
Identifiers
  • (6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide
Chemical and physical data
FormulaC26H28N4O3
Molar mass444.535 g·mol−1
3D model (JSmol)
  • O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21
  • InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
  • Key:DJXRIQMCROIRCZ-XOEOCAAJSA-N

Vibegron, sold under the brand name Gemtesa, is a medication used to treat overactive bladder.[1][5] It is used to improve the symptoms of urinary incontinence, urgency, and urinary frequency.[1] It is taken by mouth.[1]

Common side effects include headache, urinary tract infection, diarrhea, nausea, and upper respiratory tract infection.[1] Other side effects may include urinary retention.[1] Use is not recommended in people with severe kidney or liver problems.[1] Safety in pregancy is unclear.[1] It is a selective beta3 adrenergic receptor agonist.[4]

Vibegron was approved for medical use in Japan in 2018 and the United States in 2020.[1][6] It is not approved in the United Kingdom or Europe as of 2022.[6] In the United States it costs about 460 USD per month as of 2022.[7]

References[edit]

  1. ^ a b c d e f g h i j k "Gemtesa- vibegron tablet, film coated". DailyMed. Archived from the original on 14 January 2021. Retrieved 12 January 2021.
  2. ^ a b c Rechberger T, Wróbel A (January 2021). "Evaluating vibegron for the treatment of overactive bladder". Expert Opinion on Pharmacotherapy. 22 (1): 9–17. doi:10.1080/14656566.2020.1809652. ISSN 1465-6566. PMID 32993398. S2CID 222166213. Archived from the original on 2021-07-17. Retrieved 2022-09-15.
  3. ^ Urovant Sciences GmbH (2020). "HIGHLIGHTS OF PRESCRIBING INFORMATION GEMTESA" (PDF). Archived (PDF) from the original on 2021-07-17. Retrieved 2022-09-15.
  4. ^ a b "Vibegron Monograph for Professionals". Drugs.com. Retrieved 1 November 2022.
  5. ^ "Drug Trials Snapshot: Gemtesa". U.S. Food and Drug Administration (FDA). 23 December 2020. Archived from the original on 12 January 2021. Retrieved 12 January 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ a b "Vibegron". SPS - Specialist Pharmacy Service. 25 January 2016. Archived from the original on 4 December 2021. Retrieved 1 November 2022.
  7. ^ "Gemtesa". Archived from the original on 1 November 2022. Retrieved 1 November 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Vibegron&oldid=1211261824"